All In Biotech

NDA 022201 · Ferring

Firmagon

Degarelix Acetate · Subcutaneous

Novel

Last checked: Nov 19, 2026Latest source record: Feb 24, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Dec 24, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

146

40 Phase 3, 22 recruiting

FAERS reports

5,333

3,533 serious, 659 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 30, 2024.

FIRMAGON ® is indicated for treatment of patients with advanced prostate cancer. FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer. ( 1 )

Mechanism: Degarelix is a GnRH receptor antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 24, 2008 Original approval · Type 1 - New Molecular Entity NovelReviewLetterLabel
2 products under this application
  • FIRMAGON · DEGARELIX ACETATE EQ 120MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription
  • FIRMAGON · DEGARELIX ACETATE EQ 80MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Degarelix" as an intervention, any sponsor and status, largest first.

All 146 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue412
  • injection site pain367
  • hot flush329
  • injection site erythema293
  • death227
  • asthenia224
  • injection site swelling212
  • product storage error209
  • disease progression174
  • pyrexia171
  • prostatic specific antigen increased166
  • fall162

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20072
200934
201079
2011112
2012104
2013140
2014243
2015194
2016332
2017353
2018367
2019350
2020297
2021406
2022479
2023449
2024489
2025571
2026332

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Firmagon (Degarelix Acetate)

2024 spending

$1.2M

Beneficiaries

436

2,082 claims

Per beneficiary

$2,718

$501.43 per unit

View as table
YearSpending
2020$1,051,561
2021$1,225,664
2022$1,054,915
2023$1,180,364
2024$1,185,179

Part B: Firmagon (Degarelix Acetate) · HCPCS J9155

2024 spending

$17.0M

Beneficiaries

10,573

36,140 claims

Per beneficiary

$1,604

2024 ASP limit $4.25 per unit

View as table
YearSpending
2020$17,797,083
2021$18,178,465
2022$18,550,711
2023$18,164,271
2024$16,959,006

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 76 on PubMed

Sponsor: Ferring

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.